Qiu Li

Structure-Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors.

Yan Zhang, Yong Xu, H. Xu, 2022, Journal of medicinal chemistry.

Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.

Yan Zhang, Donghai Wu, Benqiang Yao, 2022, Journal of medicinal chemistry.

Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer

Yan Zhang, Yong Xu, Qiu-ping Xiang, 2019, Acta Pharmacologica Sinica.

Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.

Yan Zhang, Yong Xu, Donghai Wu, 2019, Journal of medicinal chemistry.

Livin modulates the apoptotic effects of vesicular stomatotitis virus in lung adenocarcinoma.

Z. Ding, Wei-lin Wang, Xiao-Long Zhang, 2015, International journal of oncology.

Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist.

Yan Zhang, Yong Xu, Donghai Wu, 2021, Journal of Medicinal Chemistry.

Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer

Yan Zhang, Yong Xu, Qiu-ping Xiang, 2019, Acta Pharmacologica Sinica.